Citations

Clear

15 citation(s) found for "Spinner, Michael".

Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma
Dumke, Henry , Thiruvengadam, Swetha Kambhampati, Argao, Christine, Schroers‐Martin, Joseph G. , Lanka, Sree M , Sawalha, Yazeed , Alharthy, Hanan , Ahmed, Sairah , Okcu, Izel, Nowakowski, Grzegorz S. , Doukas, Peter , Shanmugasundaram, Krithika , Colton, Meryl, Spinner, Michael A. , Rodriguez, Stefania M. , Lakin, Brock G., D’Angelo, Christopher R., Kamdar, Manali, Adewale, Olutobi, Baron, Margaret Kelsey , Bock, Allison M. , Geer, Marcus , Karimi, Yasmin , Dumke, Henry , Schroers-Martin, Joseph G , Lanka, Sree , Sawalha, Yazeed , Alharthy, Hanan , Ahmed, Sairah , Doukas, Peter G , Karmali, Reem , Shanmugasundaram, Krithika , Duvall, Adam , Pizzuti, Vincenzo J , Adewale, Olutobi , Rhodes, Joanna , Tiger, Yun Kyoung Ryu, Baron, Kelsey , Bock, Allison M , Geer, Marcus J , Karimi, Yasmin H , Yang, Xi , Thiruvengadam, Swetha Kambhampati, Karmali, Reem , Colton, Meryl D. , DuVall, Adam , D’Angelo, Christopher R. , Pizzuti, Vincenzo J. , Kamdar, Manali , Rhodes, Joanna , Tiger, Yun Kyoung

Mayo Clinic

Blood Advances | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020965 | PMID 42623675 Get It

Primary mediastinal B-cell lymphoma (PMBCL) is a rare form of large B-cell lymphoma (LBCL) with around 90% of patients cured with frontline treatment. For relapsed or refractory (R/R) disease, the optimal treatment is unclear. CD19 chimeric antigen receptor-T cell (CAR-T) has been established as the preferred second line (2L) treatment for primary refractory or early relapsing LBCL based on the overall survival benefits observed in the landmark phase III trials. However, PMBCL patients were underrepresented on these pivotal studies. This study evaluated outcomes of 252 patients treated with 2L therapies for R/R PMBCL at 14 US institutions between 2001 and 2025. Platinum-based salvage with intent to proceed to high dose therapy and autologous stem cell transplant (HDT/ASCT) (platinum cohort) and CD19 CAR-T (CAR-T cohort) were given as 2L therapy in the real-world setting in 157 and 26 patients, respectively. Overall response rate (ORR), complete response (CR) rate and median progression-free survival (PFS) were significantly higher in the CAR-T cohort compared with the platinum cohort (ORR: 91.3% vs 44.2%, p <0.001; CR 65.2% vs 14.7%, p<0.001; median PFS not reached vs 3.5 months, hazard ratio (HR) 0.28, 95% CI 0.15-0.54, p=0.001). No significant difference was observed in overall survival. This study demonstrated superior response rate and PFS of CD19 CAR-T over platinum-based salvage with intent to proceed to HDT/ASCT as 2L treatment for R/R PMBCL.
Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
Advani, Ranjana H., Kelsey, C., Armand, Philippe, Bello, Celeste, Benitez, Cecil M. , Chen, Weina , Cherian, Sheen , Czader, Magdalena , Dabaja, Bouthaina, Daly, Megan E., Gordon, L. I., Hansen, Neil, Herrera, Alex F. , Hochberg, Ephraim P. , Hoppe, Richard T., Isufi, Iris, Johnston, Patrick B., Kelly, Kara M, Kenkre, Vaishalee P. , Lynch, R., Morgan, David, Rabinovitch, R., Salavati, Ali, Sano, Dahlia , Svoboda, J., Yahalom, Joachim, Yang, Joanna C. , Stehman, Katie, Advani, Ranjana H. , Hoppe, Richard T. , Advani, Ranjana H , Hoppe, Richard T , Kelsey, Chris R. , Armand, Philippe , Bond, David A. , Dabaja, Bouthaina, Daly, Megan, Frosch, Zachary AK , Hansen, Neil, Johnston, Patrick B, Kelly, Kara M , Kline, Justin Paul , McConathy, Jonathan , Niu, Alex , Paul, Suman , Rabinovitch, Rachel , Salavati, Ali , Shah, Harsh , Spinner, Michael A. , Svoboda, Jakub , Winter, Jane N. , Yahalom, Joachim , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 41-60

10.6004/jnccn.2026.0006 | PMID 41671432 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin lymphoma provide expert, multidisciplinary recommendations for the diagnosis and treatment of Hodgkin lymphoma. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Hodgkin Lymphoma focuses on the management of newly diagnosed and relapsed/refractory classic Hodgkin lymphoma in adults aged 18 to 60 years.
Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis
Yang, Xi , Dumke, Henry, Lanka, Sree M , Okcu, Izel, Nowakowski, Grzegorz, Doukas, Peter , Colton, Meryl D. , Pizzuti, V., Adewale, Olutobi, Baron, Kelsey, Bock, Allison M. , Karimi, Yasmin , Pizzuti, Vincenzo J. , Karimi, Yasmin H , Okcu, Izel , Pizzuti, Vincenzo J , Schroers‐Martin, Joseph G. , Sawalha, Yazeed , Nowakowski, Grzegorz, Karmali, Reem , Spinner, Michael A. , Pizzuti, Vincenzo, Kamdar, Manali , Adewale, Olutobi, Tiger, Yun Kyoung , Geer, Marcus

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 783-783

10.1182/blood-2025-783 Get It

Abstract Introduction: Primary mediastinal B-Cell lymphoma (PMBCL) is a rare form of large B-Cell lymphoma (LBCL) with around 90% of patients (pts) cured with first line (1L) treatment. For pts with relapsed or refractory (RR) PMBCL, the optimal treatment is unclear. Prior retrospective analysis in the rituximab (R) era have shown high response rates to platinum salvage and high-dose chemotherapy followed by autologous stem cell transplant (HDT/ASCT) in second line (2L) RR PMBCL (Bakos et al. ASH 2023 and Dumke et al. ASCO 2024). The pivotal phase III LBCL trials in early relapsing pts that compared CD19 chimeric antigen receptor-T cell (CAR-T) with HDT/ASCT as 2L treatment had few PMBCL pts: none on ZUMA-7 and 17 PMBCL on TRANSFORM, of whom only 8 were randomized to 2L CAR-T. This study aims to evaluate outcomes of 2L therapies for RR PMBCL, including pts treated with 2L CAR-T. Methods: We performed a multicenter retrospective study in pts with RR PMBCL treated between 2001 and 2025. Clinical and pathologic characteristics, treatment regimens, and efficacy outcomes were collected and analyzed. Results: 139 pts were included with 43% male, 69% Caucasian, 7.9% Black, 8.6% Asian and 79% Non-Hispanic. R-EPOCH (64%) and (32%) were the most common 1L treatments and all pts received R. Consolidative radiation was used in 21 pts (15%) as part of 1L therapy, 28% after RCHOP. Primary refractory disease with relapse ≤6 month (mo), or early relapse ≤12 mo, occurred in 83% (N = 115) and 93% (N = 129 pts), respectively. At relapse, median age was 34 years (yrs), 44% had advanced stage disease, 31% had bulky disease (≥ 7.5cm). CNS relapse occurred in 8.6% of pts. Overall and complete response rate (ORR and CR) to any 2L treatment was 44% and 27%, respectively. At median follow-up of 40 months (mo) from the start of 2L treatment, median PFS of the entire cohort was 3.2 mo with a 3 yr OS of 70%. For 2L treatment, N=93 (67%) pts were treated with platinum salvage with intention to proceed with HDT/ASCT. Most commonly used platinum salvage regimens were ICE± R (n= 53, 38%), R-DHAP (n=23, 17%), R-GemOx (n= 5, 3.6%), and GDP ± R (n= 10, 7.2%), and the majority (95%) of pts received R with 2L therapy. ORR and CR to platinum salvage was 46% and 15% respectively. With a median follow up of 30 mo from start of 2L therapy, median PFS was 2.6 mos, and 3 yr PFS and OS was 15% and 64%, respectively. Of the 93 pts treated with platinum salvage, only 25 pts (27%) proceeded with HDT/ASCT- of whom, N = 17 (68%) achieved a CR after ASCT. In patients that proceeded to ASCT, relapses occurred in 10 pts (40%) with a 3 yr PFS and OS 56% and 83%, respectively. CAR-T was used as 2L in 20 pts (14%)- most commonly either axi-cel (N =7) or liso-cel (N = 8). ORR and CR to CART was 89% and 55% respectively, median PFS and OS was NR after CAR-T infusion and 3 yr PFS and OS was 55% and 95%, respectively. Other 2L treatments included pembrolizumab (N =3), brentuximab vedotin (BV) + nivolumab (N= 4) or single agent BV (N=2). Radiation was given as part of 2L treatment in 25.9% of pts. 2L CAR-T therapy was associated with improved ORR (OR 7.60, 95% CI 1.68 – 34.55, p = 0.002), improved CR rate (OR 4.15, 95% CI 1.49 – 11.53, p = 0.008) and improved PFS (HR 0.18, 95% CI 0.06 – 0.57, p = 0.004) compared to pts treated with 2L platinum salvage. There was no difference in OS between pts treated with platinum salvage or 2L CAR-T. A total of 96 patients progressed on 2L therapy, and 92 pts (95.8%) received third-line (3L) treatment. Third line treatments included chemoimmunotherapy +/- HDT/ASCT (N= 23), CD19 CAR-T (N = 35), clinical trial (N=7), check point inhibitor-based regimen (N= 11), BV based regimen (N= 8), allogeneic stem cell transplant (N = 3) or other (N = 5), with 7 pts receiving radiation as part of 3L therapy. Median PFS and OS from start of 3L therapy was 6.7 mo and 6.4 mo, respectively. Conclusions: We report the largest cohort of pts with RR PMBCL treated in the rituximab era and the largest number of PMBCL pts treated with 2L CAR-T. This is the first analysis, to our knowledge, to show a statistically significant benefit in PFS, ORR and CR rate of CAR-T compared to platinum salvage followed by HDT/ASCT as 2L treatment in a study of exclusively RR PMBCL pts. Our dataset was largely (93%) compromised of pts with primary refractory or early relapsing disease and provides support for using CAR-T as 2L treatment in this high-risk subset of RR PMBCL patients.
Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy
Cherng, Hua-Jay, Gerber, Drew, Nze, Chijioke, Bhayani, Shahzeem, Russler-Germain, David, Alnughmush, Ahmed, Hampel, Paul, Kille, Kelsey, Wallace, Danielle, Qualls, David, Merryman, Reid, Brooks, Jaden, Bock, Allison, Ramirez, Juan, Zhang, Yumeng, Chavez, Julio, Granger, Katelynn, Antel, Katherine, Duarte, Cassandra, Major, Ajay, Ma, Sirui, Spinner, Michael, Mackay, Alyssa, Hu, Bei, Rai, Manoj, Spurgeon, Stephen, Lee, Benjamin, Doh, Jean, Brem, Elizabeth, Altomare, Nicole, Karmali, Reem, Ryan, Robert, Tiger, Yun Kyoung, Carter, Jordan, Landsburg, Daniel, Thiruvengadam, Swetha, Skarbnik, Alan, Choi, Yun, Bond, David, Samaeekia, Ravand, Ma, Helen, Tolu, Seda, Amengual, Jennifer, Herrera, Alex, Pro, Barbara, Qualls, David , Qualls, David A , Cherng, Hua-Jay, Gerber, Drew, Nze, Chijioke, Bhayani, Shahzeem, Russler-Germain, David, Alnughmush, Ahmed, Hampel, Paul, Kille, Kelsey, Wallace, Danielle, Merryman, Reid, Brooks, Jaden, Bock, Allison, Ramirez, Juan, Zhang, Yumeng, Chavez, Julio, Granger, Katelynn, Antel, Katherine, Duarte, Cassandra, Major, Ajay, Ma, Sirui, Spinner, Michael, Mackay, Alyssa, Hu, Bei, Rai, Manoj, Spurgeon, Stephen, Lee, Benjamin, Doh, Jean, Brem, Elizabeth, Altomare, Nicole, Karmali, Reem, Ryan, Robert, Tiger, Yun Kyoung, Carter, Jordan, Landsburg, Daniel, Thiruvengadam, Swetha, Skarbnik, Alan, Choi, Yun, Bond, David, Samaeekia, Ravand, Ma, Helen, Tolu, Seda, Amengual, Jennifer, Herrera, Alex, Pro, Barbara

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 471-471

10.1182/blood-2025-471 Get It

Abstract Background: For LS-DLBCL, clinical trials (FLYER, LYSA/GOELAMS 02-03, LYSA LNH09-1B, S1001) have shown that 4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP4) without radiation (RT) leads to durable remissions in >90% of cases. However, only patients (pts) with non-bulky disease and/or international prognostic index (IPI) of 0 and complete metabolic response (CMR) on interim positron emission tomography (PET) scan, if performed, were eligible for RCHOP4 alone in these studies. Outcomes in trial-ineligible LS-DLBCL and the appropriate real-world candidates for RCHOP4 are still undefined. Methods: We conducted a multicenter retrospective study of adult pts with stage I/II DLBCL of any tumor bulk, IPI and with or without B-symptoms diagnosed after 2011 and treated with RCHOP4 +/- 2 cycles R from 21 U.S. centers. Pts with PMBCL, PTLD or receiving non-standard dose RCHOP for cycle (C) 1 or planned consolidative RT were excluded. The primary endpoint was PFS from C1 by Kaplan-Meier method, not counting indolent lymphoma relapse. Event free survival (EFS) was time to next therapy without progression (including unplanned RT for non-CR), progression or death. A competing risks analysis of non-relapse mortality (NRM) vs. DLBCL progression was performed. Results: The characteristics of the 428 pts were: median age 60 (18-88), 60% male, 11% Hispanic and 4% non-Hispanic Black, 62% stage I, 15% elevated LDH, 3% ECOG PS>1, 5% tumor bulk >7cm, 9% had B-symptoms and median Charlson Comorbidity Index (CCI) was 4 (2-12). IPI was 0, 1 and 2-3 in 42%, 46% and 12% and stage-modified IPI (smIPI) was 0, 1, 2 and 3-4 in 25%, 48%, 21% and 6% of pts. 66% had nodal (59% head/neck, 11% pelvic, 9% multiple above diaphragm, 7% abdominal) and 46% extranodal sites (37% head/neck, 20% gastric/intestinal, 9% spleen, 8% skin/soft tissue); 6% had transformed/concurrent FL/MZL or grade 3B FL, 33% (138/408) were non-GCB cell of origin (COO), 25% (90/357) double expressor (DEL) and 0.5% (2/379) double-hit. 13% had completely resected disease, 97% staging PET and 47% bone marrow biopsy. Median diagnosis to treatment interval was 30 days (IQR 20-43), 6% had dose reductions after C1, 77% had an interim PET (iPET) after C2 (33%) or C3 (67%), 15% received 2 additional cycles R and 4% CNS prophylaxis. CMR rates by iPET were 83% after C2 and 94% after C3, and 95% by end-of-treatment PET. iPET PMR was more likely if smIPI>2 or bulky disease. Median follow-up time was 2.7 years. There were 32 progression events: 14 occurred at the primary site and 17 at distant sites (1 unknown), and 12 occurred after 2 years. Another 11 pts received unplanned RT after RCHOP4 for non-CR. There were 24 deaths, 12 without prior progression. Cause of death was DLBCL in 7 and non-DLBCL in 17 cases (6 infection, 2 ILD, 2 heart failure, 2 second cancer, 1 seizure, 4 unknown). EFS, PFS and OS rates were 88%, 90% and 96% at 3 years. By univariable Cox regression, Black race, elevated LDH, smIPI>2, DEL, increasing CCI, multiple subdiaphragmatic nodal sites and iPET PMR were associated with worse PFS. Non-significant variables of note included COO, extranodal sites, complete resection, missing bone marrow biopsy, missing iPET and additional cycles R. By multivariable analysis (including age>60, stage, ECOG PS>1, elevated LDH, bulky disease, CCI, B-symptoms and DEL), ECOG PS>1 (HR 3.95 p=0.050), CCI (HR 1.29 p=0.003) and DEL (HR 2.02 p=0.069) were associated with worse PFS. Cumulative incidence of DLBCL progression and NRM were 8% and 2% at 3 years. Competing risk analysis by univariable models found that age>60, ECOG PS>1, smIPI>2, elevated LDH, CCI and bulky disease were associated with NRM, while DEL and B-symptoms were associated with DLBCL progression.Conclusion: Presented is the largest retrospective cohort of LS-DLBCL treated uniformly with RCHOP4 to date. Despite modest follow-up time and lack of an “intention-to-treat“ population, this study shows that abbreviated RCHOP4 leads to excellent outcomes in the real-world, albeit with continuous risk of late relapse. smIPI risk factors were associated with worse PFS, though this may in part be driven by risk of non-lymphoma death. As pts with advanced age, poor performance status or comorbidities may benefit from reduced treatment exposure, RCHOP4 should still be considered for these and other “trial-ineligible” pts, particularly if other high-risk features (iPET PMR, DEL or B-symptoms) are absent.
419 | MULTICENTER REAL‐WORLD OUTCOMES IN DIFFUSE LARGE B‐CELL LYMPHOMA PROFILED WITH A COMMERCIALLY‐AVAILABLE CIRCULATING TUMOR DNA ASSAY
Gould, P., Ma, Xin , Ananth, Sudha , Rose, Alan, Lattin, John , Skarbnik, Alan P , Bock, Allison M. , Baron, Kelly Glazer , Hess, Brian , Ayers, Edward L., Pro, Barbara, Vaidya, S., Amengual, Jennifer E. , Godbole, S., Bond, David A. , Ananth, S., Jacobs, Ryan W. , Hu, Bei , Stanchina, Michele , Rose, A., Russler‐Germain, David A. , Randall, Michael P. , Spinner, Michael A. , Duarte, C., Major, Ajay , Baron, K., Ip, Andrew , Tsang, Mazie , Ayers, E., Tolu, Seda , Reshef, Ran , Cherng, Hua‐Jay J.

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_419 Get It

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
Šýkorová, Alice , Evens, Andrew M. , Dorritie, Kathleen , Kenkre, Vaishalee P. , Chang, Cheryl , Michalka, Jozef , Ansell, Stephen M. , Fusco, Brendon , Hatic, Haris, Saba, Raya , Harris, Elyse I., Wagner‐Johnston, Nina D. , Arai, Sally , Nowakowski, Grzegorz S. , Móciková, Heidi , Jagadeesh, Deepa, Blum, Kristie A. , Iyengar, Siddharth , Rappazzo, K. C., Choi, Yun Young , Advani, Ranjana H. , Micallef, Ivana N. , Advani, Ranjana H , Evens, Andrew M , Desai, Sanjal H. , Spinner, Michael A. , Bachanová, Veronika , Goyal, Gaurav , Kahl, Brad S. , Azzi, Jacques Mario , Sumransub, Nuttavut , Ibrahim, Uroosa , Shah, Harsh , Jagadeesh, Deepa , Diefenbach, Catherine , Baidoun, Firas , Procházka, Vít

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 570-570

10.1182/blood-2024-199845 Get It

Introduction: Adults older than 60 years constitute 20-25% of newly diagnosed classic Hodgkin lymphoma (cHL) and have inferior outcomes compared to younger patients (pts). Salvage therapy followed by an autologous stem cell transplant (ASCT) is a potentially curative option for pts with relapsed/refractory (R/R cHL). There is limited data regarding outcomes of older adults with R/R cHL who undergo ASCT in the current era where novel agents are employed in the R/R setting, in comparison with younger patients. Methods: This multicenter, international, retrospective study of 18 participating institutions included adults with R/R cHL who underwent ASCT from January 1, 2010 through December 31 2020. Retrospective chart review was performed to collect data on patient and disease characteristics at relapse, including lines and type of salvage therapy, pre-ASCT response by PET, and use of brentuximab vedotin (BV) as consolidation post-ASCT. Study objectives were to assess progression-free survival (PFS), overall survival (OS), and the probability of non-relapse mortality (NRM) with relapse as a competing event. NRM was defined as death without preceding relapse. Results: Of the total 1172 adults with R/R cHL enrolled in the parent cohort, 96 (8.1%) were age 60 years or older at the time of ASCT. In this older cohort, the median age was 66 years (range: 60-72). 54 (56%) were age 60-64, 31 (32%) were of age 65-69 and 11 (11%) were of age 70-72. 59 (61%) were male, 63 (66%) had advanced stage disease, 17 (18%) had bulky disease, 37 (39%) had B symptoms and 38 (40%) had extranodal disease. All patients (pts) received ABVD or ABVD-like frontline therapy. The median time to relapse was 6 months (range: 0-174). 48 pts (50%) relapsed within a year after completion of frontline treatment and 25 (26%) had primary refractory disease. Salvage therapy prior to ASCT included platinum-based chemotherapy (65%), BV-based regimen (34%), and PD-1 inhibitor-based regimens (3%). 16 pts (16%) underwent ASCT after >1 line of salvage therapy and 75 (78%) underwent ASCT after achieving a complete metabolic response (CMR). 14 pts (14.6%) received BV consolidation. Median follow-up for entire population was 53.4 months (range: 0.3-199.0). In older adults, the 5-year PFS was 54.2% (CI95: 43.4-67.6) not statistically different compared to pts <60 years (67.7% (CI95: 64.3-71.3), p=0.2). However, 5-year OS was inferior in older adults: 71.9% (CI95: 43.4-67.6) vs. 82.6% (CI95: 43.4-67.6) in pts <60 years (p <0.0001)). In pts ≥60, 26 (27%) died including 12 (12.5%) without preceding relapse. Older adults had 3-month, 1-year and 5-year probability of NRM of 5.2% (CI95: 2.2-12.2), 7.5% (CI95: 3.6-15.3), and 10.9% (CI95: 5.8-20.8), respectively. NRM was significantly higher in older adults compared to pts <60 who had 3-month, 1-year and 5-year probability of NRM of 0.3% (CI95: 0.1-1.0), 0.9% (CI95: 0.5-1.7), and 2.5% (CI95: 1.6-3.9), respectively (p<0.0001). Older adults had 3-month, 1-year and 5-year probability of relapse of 1% (CI95: 0.2-7.3), 7.5% (CI95: 3.6-15.3), and 28.6% (CI95: 19.1-42.1), respectively, which did not differ significantly from younger pts (p=0.3) who had 3-month, 1-year and 5-year probability of relapse of 0.6% (CI95: 0.3-1.3), 5.1% (CI95: 3.8-6.6), and 29.9% (CI95: 26.6-33.5), respectively. Conclusions: Although older adults with cHL are more likely to relapse after frontline treatment, only a minority of pts (<10%) in this large multicenter cohort underwent ASCT at age ≥60. In select older adults who underwent ASCT, the risk of relapse was similar to younger pts, but NRM was significantly higher, especially in the early post-ASCT period. Detailed assessment of comorbidity scores, toxicities of salvage therapies, and prognostic factors will be presented at the conference.
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
Desai, Sanjal H. , Evens, Andrew M. , Šýkorová, Alice , Bachanová, Veronika , Goyal, Gaurav , Dorritie, Kathleen , Azzi, Jacues, Kenkre, Vaishalee P. , Chang, Cheryl , Michalka, Jozef , Ansell, Stephen M. , Fusco, Brendon , Hatic, Haris, Saba, Raya , Harris, Elyse I., Wagner‐Johnston, Nina D. , Arai, Sally , Nowakowski, Grzegorz S. , Móciková, Heidi , Jagadeesh, Deepa , Blum, Kristie A. , Diefenbach, Catherine , Iyengar, Siddharth , Rappazzo, Katherine , Choi, Yun Young , Advani, Ranjana H. , Micallef, Ivana N. , Evens, Andrew M , Goyal, Guarav , Dorritie, Kathleen , Sumransub, Nuttavut , Ibrahim, Uroosa , Wagner-Johnston, Nina , Arai, Sally , Mocikova, Heidi , Prochazka, Vit , Micallef, Ivana, Bachanova, Veronika , Advani, Ranjana H , Desai, Sanjal , Diefenbach, Catherine S , Spinner, Michael A. , Kahl, Brad S. , Shah, Harsh , Baidoun, Firas , Procházka, Vít

Mayo Clinic

Blood Advances | September 20, 2023 | Volume: 7 | Issue: 23 | Pages: 7295-7303

10.1182/bloodadvances.2023011205 | PMID 37729621 Get It

Abstract In the pre–novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved the depth and durability of response in this population. Here, we report the estimate of PPS in patients with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult patients with relapsed cHL after ASCT were included. Study objective was postprogression overall survival (PPS), defined as the time from posttransplant progression to death or last follow-up. Of 1158 patients who underwent ASCT, 367 had progressive disease. Median age was 34 years (range, 27-46) and 192 were male. Median PPS was 114.57 months (95% confidence interval [CI], 91-not achieved) or 9.5 years. In multivariate analysis, increasing age, progression within 6 months, and pre-ASCT positive positron emission tomography scan were associated with inferior PPS. When adjusted for these features, patients who received CPI, but not BV, as first treatment for post-ASCT progression had significantly higher PPS than the no CPI/no BV group (hazard ratio, 3.5; 95% CI, 1.6-7.8; P = .001). Receipt of allogeneic SCT (Allo-SCT) did not improve PPS. In the era of novel agents, progressive cHL after ASCT had long survival that compares favorably with previous reports. Patients who receive CPI as first treatment for progression had higher PPS. Receipt to Allo-SCT was not associated with PPS in this population.